Trials / Completed
CompletedNCT03293407
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real life setting. The study was not designed to investigate or confirm the effectiveness and safety of iloprost.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloprost (Ventavis, BAYQ6256) | Using Breelib device |
| DEVICE | Breelib nebulizer | Used for inhalation of Ventavis |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2019-10-09
- Completion
- 2020-01-20
- First posted
- 2017-09-26
- Last updated
- 2021-05-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03293407. Inclusion in this directory is not an endorsement.